)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Innovent Biologics (1801) investor relations material
Innovent Biologics H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary27 Aug, 2025
Executive summary
Achieved total revenue of RMB5,953.1 million for 2025H1, up 50.6% year-over-year, driven by robust oncology and general biomedicine sales, and increased license income.
Net profit reached RMB834.3 million, a turnaround from a loss of RMB392.6 million in the prior year, with Non-IFRS net profit at RMB1,213.2 million and EBITDA at RMB1,412.8 million, reflecting improved operational efficiency.
Five new products launched, expanding the portfolio to 16 marketed products, sustaining oncology leadership and driving growth in general biomedicine.
Strategic collaborations, including a global license agreement with Roche for IBI3009, and global R&D expansion underpin international growth ambitions.
Cash reserves exceeded USD2.0 billion as of July 31, 2025, providing a strong financial base for future growth.
Financial highlights
Revenue: RMB5,953.1 million (+50.6% YoY); product revenue: RMB5,233.8 million (+37.3% YoY); license fee income: RMB665.6 million (up from RMB115.9 million YoY).
Gross profit: RMB5,119.6 million (+56.3% YoY); gross margin increased to 86.8% (Non-IFRS: 86.8%).
SG&A expenses ratio decreased by 7.9pp to 44.2%, and selling and marketing expenses were RMB2,375.1 million (39.9% of revenue).
Net profit: RMB834.3 million (vs. loss of RMB392.6 million YoY); Non-IFRS net profit: RMB1,213.2 million; Non-IFRS EBITDA: RMB1,412.8 million.
Cash and cash equivalents stood at over RMB11bn (USD1.5bn) as of June 30, 2025, and USD2bn as of July 31, 2025.
Outlook and guidance
2025 is positioned as a pivotal year, with continued revenue growth expected from oncology and new launches in general biomedicine.
Anticipates approvals for IBI112 and IBI310 by end of 2025, and further product launches and expanded indications.
Advancing global registrational studies for IBI363 and IBI343, with new PoC studies and Ph1 data accumulation planned.
Ongoing global expansion with late-stage clinical trials and regulatory submissions in multiple regions.
Three-year plan targets 20 commercial products and RMB20bn product revenue by 2027.
When does IBI363 global Phase 3 enrollment start?
What drove the reduction in R&D expenses?
When is Mazdutide's head-to-head data vs. semaglutide?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Innovent Biologics earnings date
H2 202525 Mar, 2026
Next Innovent Biologics earnings date
H2 202525 Mar, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Innovent Biologics Inc. is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of biologic drugs, primarily targeting oncology, autoimmune, metabolic, and ophthalmology diseases. The company develops monoclonal antibodies and other biologic therapies aimed at addressing unmet medical needs, particularly within the Chinese market. The company is headquartered in Suzhou, China, and its shares are listed on the Hong Kong Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage